Document Detail


Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results.
MedLine Citation:
PMID:  17006704     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The objective of this study was to present our clinical experience about scleroderma-related pulmonary hypertension in the patients treated with intermittent iloprost infusions. Eighty-one patients affected by systemic sclerosis (12 men, 69 women; 30 with diffuse pattern and 51 with limited pattern; mean age 55.1 years; mean duration of disease 105.3 months) have been treated with cyclic iloprost infusions for at least 15 months (range 15-126 months). During the last 4 months all patients underwent Doppler echocardiography in order to estimate the value of systolic pulmonary artery pressure. In 14 subjects (17.2%) systolic pulmonary artery pressure was = or > 35 mmHg. Four patients presented high systolic pulmonary artery pressure associated with pulmonary fibrosis (mean value 40.5 +/- 4.5 mmHg). Ten women (one with diffuse pattern of disease and nine with limited form) showed isolated high systolic pulmonary artery pressure; one of these patients underwent right heart catheterization which resulted normal. The remaining nine patients (mean age of 67.1 years; age at the onset of scleroderma 52.2 years) showed estimated systolic pulmonary artery pressure values between 35 and 50 mmHg. Among these patients affected by isolated pulmonary hypertension only one has been receiving bosentan in association with iloprost infusions. None of our scleroderma patients treated with cyclic iloprost infusions developed severe isolated pulmonary hypertension. In systemic sclerosis the multiple effects of iloprost on endothelium, platelets and cytokine network may counteract the vasospastic profile of lung microvasculature in pulmonary arterial hypertension and the consequent vascular wall remodelling, thus preventing the development of severe illness.
Authors:
Paola Caramaschi; Alessandro Volpe; Ilaria Tinazzi; Lisa Maria Bambara; Antonio Carletto; Domenico Biasi
Related Documents :
21683934 - Radiological anatomy of the ethmoidal arteries: ct cadaver study.
9806704 - The effect of the prone position on pulmonary mechanics is frame-dependent.
1877674 - Sustained effects of endothelin-1 on rabbit, dog, and rat pulmonary circulations.
9929404 - Non-invasive estimation of pulmonary arterial hypertension in chronic obstructive pulmo...
2089544 - Localized retinal detachment with combined central retinal artery and vein occlusion af...
20082464 - Fbn1 mutations in patients with descending thoracic aortic dissections.
Publication Detail:
Type:  Clinical Trial; Journal Article     Date:  2006-09-28
Journal Detail:
Title:  Rheumatology international     Volume:  27     ISSN:  0172-8172     ISO Abbreviation:  Rheumatol. Int.     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2007-01-09     Completed Date:  2007-10-23     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8206885     Medline TA:  Rheumatol Int     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  203-5     Citation Subset:  IM    
Affiliation:
Dipartimento di Medicina Clinica e Sperimentale, Università di Verona, Policlinico GB Rossi, P.le Scuro, 37134 Verona, Italy. paola.caramaschi@azosp.vr.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Epoprostenol / analogs & derivatives
Female
Humans
Hypertension, Pulmonary / etiology,  prevention & control*
Iloprost / administration & dosage*
Infusions, Intravenous
Male
Middle Aged
Pilot Projects
Scleroderma, Systemic / complications,  drug therapy*
Vasodilator Agents / administration & dosage*
Chemical
Reg. No./Substance:
0/Vasodilator Agents; 35121-78-9/Epoprostenol; 78919-13-8/Iloprost

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Hypertrophic pulmonary osteoarthropathy (HPOA) (Pierre Marie-Bamberger syndrome): two cases presenti...
Next Document:  Immunogenicity, efficacy and adverse events of adalimumab in RA patients.